Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 2
1948 5
1949 3
1950 1
1951 3
1952 5
1953 4
1954 1
1955 4
1956 3
1957 2
1958 1
1959 1
1960 1
1961 1
1962 2
1966 1
1968 2
1972 1
1973 1
1974 2
1975 1
1976 1
1977 1
1979 1
1980 1
1981 2
1982 8
1983 6
1984 7
1985 5
1986 13
1987 9
1988 8
1989 10
1990 16
1991 12
1992 15
1993 12
1994 18
1995 30
1996 26
1997 22
1998 15
1999 35
2000 31
2001 35
2002 40
2003 28
2004 35
2005 48
2006 51
2007 41
2008 46
2009 42
2010 58
2011 73
2012 73
2013 91
2014 88
2015 79
2016 98
2017 98
2018 121
2019 106
2020 115
2021 126
2022 79
Text availability
Article attribute
Article type
Publication date

Search Results

1,711 results
Results by year
Filters applied: . Clear all
Page 1
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. Shaw AT, et al. Among authors: bauer tm. N Engl J Med. 2020 Nov 19;383(21):2018-2029. doi: 10.1056/NEJMoa2027187. N Engl J Med. 2020. PMID: 33207094 Clinical Trial.
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Wirth LJ, et al. Among authors: bauer tm. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. N Engl J Med. 2020. PMID: 32846061 Clinical Trial.
Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM, Felip E, Solomon BJ, Thurm H, Peltz G, Chioda MD, Shaw AT. Bauer TM, et al. Oncologist. 2019 Aug;24(8):1103-1110. doi: 10.1634/theoncologist.2018-0380. Epub 2019 Mar 19. Oncologist. 2019. PMID: 30890623 Free PMC article.
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, Merchan JR, McDermott DF, Michaelson MD, Appleman LJ, Thamake S, Perini RF, Zojwalla NJ, Jonasch E. Choueiri TK, et al. Among authors: bauer tm. Nat Med. 2021 May;27(5):802-805. doi: 10.1038/s41591-021-01324-7. Epub 2021 Apr 22. Nat Med. 2021. PMID: 33888901 Free PMC article. Clinical Trial.
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. Shaw AT, et al. Among authors: bauer tm. J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892989 Free PMC article. Clinical Trial.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: bauer tm. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Among authors: bauer tm. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
Regulatory myeloid cells paralyze T cells through cell-cell transfer of the metabolite methylglyoxal.
Baumann T, Dunkel A, Schmid C, Schmitt S, Hiltensperger M, Lohr K, Laketa V, Donakonda S, Ahting U, Lorenz-Depiereux B, Heil JE, Schredelseker J, Simeoni L, Fecher C, Körber N, Bauer T, Hüser N, Hartmann D, Laschinger M, Eyerich K, Eyerich S, Anton M, Streeter M, Wang T, Schraven B, Spiegel D, Assaad F, Misgeld T, Zischka H, Murray PJ, Heine A, Heikenwälder M, Korn T, Dawid C, Hofmann T, Knolle PA, Höchst B. Baumann T, et al. Among authors: bauer t. Nat Immunol. 2020 May;21(5):555-566. doi: 10.1038/s41590-020-0666-9. Epub 2020 Apr 23. Nat Immunol. 2020. PMID: 32327756
Using Patient Portals to Improve Patient Outcomes: Systematic Review.
Han HR, Gleason KT, Sun CA, Miller HN, Kang SJ, Chow S, Anderson R, Nagy P, Bauer T. Han HR, et al. Among authors: bauer t. JMIR Hum Factors. 2019 Dec 19;6(4):e15038. doi: 10.2196/15038. JMIR Hum Factors. 2019. PMID: 31855187 Free PMC article. Review.
1,711 results